Last reviewed · How we verify
Pomalidomide and Dexamethasone — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pomalidomide and Dexamethasone (Pomalidomide and Dexamethasone) — Fondazione IRCCS Policlinico San Matteo di Pavia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pomalidomide and Dexamethasone TARGET | Pomalidomide and Dexamethasone | Fondazione IRCCS Policlinico San Matteo di Pavia | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pomalidomide and Dexamethasone CI watch — RSS
- Pomalidomide and Dexamethasone CI watch — Atom
- Pomalidomide and Dexamethasone CI watch — JSON
- Pomalidomide and Dexamethasone alone — RSS
Cite this brief
Drug Landscape (2026). Pomalidomide and Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/pomalidomide-and-dexamethasone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing